Drug Profile
PAM 4
Alternative Names: PAM4Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pancreatic cancer